Early Biomarker Identification and Treatment Strategy for Alzheimer's Disease

Dear Colleagues,

Alzheimer’s disease (AD) remains a formidable neurodegenerative disorder, characterized by the absence of a definitive cure and limited therapeutic efficacy in its advanced stages, and in the clinical management of which early diagnosis poses a critical challenge. Recent research has made substantial strides in identifying novel biomarkers, encompassing a diverse range of substances such as neuroimaging signals, cerebrospinal fluid (CSF) proteins, extracellular vesicle-derived RNA, blood-based markers, and advanced proteomics and metabolomics signatures. These biomarkers hold the potential to facilitate detection at the prodromal or even preclinical stages of the disease. 

This Special Issue invites original research articles, systematic reviews, bioinformatics, and cutting-edge perspectives on the development and validation of early biomarkers for AD. Furthermore, we welcome submissions exploring innovative therapeutic approaches that aim to intervene during the early stages of disease progression. The topics covered may include molecular mechanisms underlying biomarker alterations, omics-based discoveries, machine learning for predictive modeling, and preclinical or clinical trial data pertaining to early-stage interventions. By compiling contributions from these diverse perspectives, this Special Issue endeavors to advance the future of personalized diagnostics and targeted therapies in AD.

Dr. A. N. M. Mamun-Or-Rashid
Dr. Tanzima Tarannum Lucy
Prof. Dr. Amos D. Korczyn
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.